ARON-3 Study International Retrospective Research on Treatments for Metastatic Prostate Cancer Including Hormone-Sensitive and Castration-Resistant Patients Receiving ADT, ARSI, Docetaxel, Lutetium-177 PSMA, or PARP Inhibitors

What this Trial Is About

This research aims to gather and analyze real-world data on treatments for patients with metastatic prostate cancer in three specific settings. It focuses on patients with metastatic hormonecastration-sensitive prostate cancer mCSPC treated with androgen deprivation therapy ADT plus androgen receptor signaling inhibitors ARSI or with ADT, ARSI, and docetaxel. It also includes patients with metastatic castration-resistant prostate cancer mCRPC treated with Lutetium-177 PSMA therapy or with PARP inhibitors either alone or combined with ARSI, aiming to understand treatment outcomes across these groups. The study involves observing patients treated with various combinations ADTARSI or ADTARSIdocetaxel for mCSPC Lutetium-177 PSMA therapy for mCRPC and PARP inhibitors such as olaparib, niraparib, or talazoparib alone or with ARSI for mCRPC. These treatments reflect routine clinical management rather than investigational interventions. The study collects data retrospectively from these three patient groups to assess their treatment experiences and outcomes. Participants medical records and treatment histories will be reviewed to evaluate outcomes like overall survival, progression-free survival, and overall response rates for each treatment group. The study also examines time to progression based on metastatic sites and explores how lifestyle and other medications might influence outcomes. This observational study spans from January 31, 2024, to May 31, 2024, focusing on real-world treatment effects without requiring additional interventions or visits from participants.

ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa